Abstract: Gender specific synthetic nutritional compositions for female or male infants of 1 to 2 months of age wherein, the concentration of arginine is adapted based on that found in HM produced for an infant of the same gender and age, and nutritional systems comprising them.

Abstract: Gender specific synthetic nutritional compositions for infants of up to 2 months of age wherein, the concentration of alpha-lactalbumin is adapted based on that found in HM produced for an infant of the same gender and age, and nutritional systems comprising them.

Abstract: Gender specific synthetic nutritional compositions for infants up to 1 month of age, wherein the leucine and/or threonine and/or tyrosine content is adapted based on that found in HM produced for an infant of the same gender and age, and nutritional systems comprising them.

Abstract: Gender specific synthetic nutritional compositions for infants up to 1 month of age wherein, the caseins content is adapted based on that found in HM produced for an infant of the same gender and age, and nutritional systems comprising them.

Abstract: Gender specific synthetic nutritional compositions for infants up to 1 month of age wherein, the lactoferrin and/or serum albumin content is adapted based on that found in HM produced for an infant of the same gender and age, and nutritional systems comprising them.

Abstract: A composition including protein hydrolysates derived from milk is obtained by the treatment of enzymes derived from microorganisms. A trypsin-like enzyme and a chymotrypsin-like enzyme are used. The composition is in particular intended for inducing tolerance in infants with the effect of modulating the potential occurrence of allergies later in life. The composition can also be used in sick adult patients. Preferably the composition is an infant formula, infant follow-up formula, growing-up milk or baby food or an enteral complete nutritional composition.

Abstract: A composition including protein hydrolysates derived from milk is obtained by the treatment of enzymes derived from microorganisms. A trypsin-like enzyme and a chemotrypsin-like enzyme are used. The composition is in particular intended for inducing tolerance in infants with the effect of modulating the potential occurrence of allergies later in life. The composition can also be used in sick adult patients. Preferably the composition is an infant formula, infant follow-up formula, growing-up milk or baby food or an enteral complete nutritional composition.

Abstract: The present invention relates to novel strains of Lactobacillus helveticus that can produce high amounts of hypotensive peptides, in particular IPP, VPP and LPP. It also relates to a fermented milk product containing a mixture of tripeptides IPP-VPP-LPP and a strain of L. helveticus. The invention further relates to the specific peptide mixture consisting of tripeptides IPP, VPP and LPP and the use of the fermented product or mixture of peptides in food products, food supplement or pharmaceutical compositions for reducing or preventing hypertension.

Abstract: A composition comprising protein hydrolysates derived from milk is obtained by the treatment of enzymes derived from microorganisms. A trypsin-like enzyme and a chemotrypsin-like enzyme are used. The composition is in particular intended for inducing tolerance in infants with the effect of modulating the potential occurrence of allergies later in life. The composition can also be used in sick adult patients. Preferably the composition is an infant formula, infant follow-up formula, growing-up milk or baby food or an enteral complete nutritional composition.

Abstract: The present invention relates to novel strains of Lactobacillus helveticus that can produce high amounts of hypotensive peptides, in particular IPP, VPP and LPP. It also relates to a fermented milk product containing a mixture of tripeptides IPP-VPP-LPP and a strain of L. helveticus. The invention further relates to the specific peptide mixture consisting of tripeptides IPP, VPP and LPP and the use of the fermented product or mixture of peptides in food products, food supplement or pharmaceutical compositions for reducing or preventing hypertension.

Abstract: The present invention refers to a koji mold capable of expressing proteolytic enzymes in the presence of a carbon source in at least the same amount as in the absence thereof. In particular, the present invention pertains to a mutation in the creA gene as a tool to increase the amount of a wide spectrum of proteolytic enzymes in the presence of a carbon source.

Abstract: The present invention is directed to procedures for the controlled natural bioprocessing of naturally occurring biological molecules by processing activities present in select organisms, extracts of such organisms or other natural processing agents. The invention also covers the methods for developing these procedures and compositions prepared by the procedures.

Abstract: A novel, soluble protein similar to the known Toll-like receptor (TLR) family is disclosed. The present invention relates to these new soluble polypeptides, to nucleotide sequences encoding the polypeptides, to antibodies selectively binding to the polypeptide and to expression systems suitable for producing the polypeptide. The polypeptide is useful for modulating inflammatory reactions in mammals that include the actions of TLR.

Abstract: The present invention is directed to procedures for the controlled natural bioprocessing of naturally occurring biological molecules by processing activities present in select organisms, extracts of such organisms or other natural processing agents. The invention also covers the methods for developing these procedures and compositions prepared by the procedures.

Abstract: A novel, soluble protein similar to the known Toll-like receptor (TLR) family is disclosed. The present invention relates to these new soluble polypeptides, to nucleotide sequences encoding the polypeptides, to antibodies selectively binding to the polypeptide and to expression systems suitable for producing the polypeptide. The polypeptide is useful for modulating inflammatory reactions in mammals that include the actions of TLR.

Abstract: This invention relates to a process for the production of a cultured savory base by hydrolyzing a protein-containing material using a combination of at least one enzyme with at least one thermotolerant lactic acid bacteria strain selected for its ability to provide a glutaminase activity. The invention also relates to an isolated strain of thermotolerant lactic acid bacteria strains selected for their ability to provide a glutaminase activity and their use for preparing a seasoning or flavor for culinary or petfood products.

Abstract: This invention relates to a process for the production of a cultured savory base by hydrolyzing a protein-containing material using a combination of at least one enzyme with at least one thermotolerant lactic acid bacteria strain selected for its ability to provide a glutaminase activity. The invention also relates to an isolated strain of thermotolerant lactic acid bacteria strains selected for their ability to provide a glutaminase activity and their use for preparing a seasoning or flavor for culinary or petfood products.

Abstract: The invention has for object the new recombinant prolyl-dipeptidyl-peptidase enzyme (DPP IV) from Aspergillus oryzae comprising the amino-acid sequence from amino acid 1 to amino acid 755 of SEQ ID NO:2 or functional derivatives thereof, and providing a high level of hydrolyzing specificity towards proteins and peptides starting with X-Pro- thus liberating dipeptides of X-Pro type, wherein X is any amino acid. The invention also provides a DNA molecule encoding the enzyme according to the invention, cells expressing the enzyme according to the invention by recombinant technology, an Aspergillus naturally providing a prolyl-dipeptidyl-peptidase activity which has integrated multiple copies of the Aspergillus native promoter which naturally directs the expression of the gene encoding the prolyl-dipeptidyl-peptidase activity, Aspergillus naturally providing a prolyl-dipeptidyl-peptidase activity which is manipulated genetically so that the dppIV gene is inactivated.

Abstract: The present invention has for an object a koji mold which expresses at least 2 times more endo- and exo-peptidases than the wild type strain of Aspergillus oryzae CNCM I-1882, and especially at least 30 mU of endopeptidase activity, at least 30 mU of leucine-amino-peptidase and at least 10 mU of prolyldipeptidyl-peptidase activity per ml of supernatant when grown in a minimal medium containing 0.2% soy bean proteins. The invention also provides a DNA-binding protein of Aspergillus oryzae (AREA) having at least the amino-acid sequence from amino-acid 1 to amino-acid 731 of SEQ ID NO:2 or functional derivatives thereof. The invention also provides a DNA molecule that comprises an areA gene encoding the DNA-binding protein according to the invention.